Low fixed-dose hydroxyurea in severely affected Indian children with sickle cell disease

Hemoglobin

Volumn 36, Issue 4, 2012, Pages 323-332

  Jain, Dipty L ^a   Sarathi, Vijaya ^a   Desai, Saumil ^a   Bhatnagar, Manoj ^a   Lodha, Abhijit ^a  

^a GOVERNMENT MEDICAL COLLEGE   (India)

Author keywords

Blood transfusions; Hospitalizations; Hydroxyurea (HU); Sickle cell disease; Vasoocclusive crises

Indexed keywords

HEMOGLOBIN; HEMOGLOBIN F; HYDROXYUREA; PLACEBO;

ADOLESCENT; ADULT; ALOPECIA; ARTICLE; BLOOD TRANSFUSION; CHILD; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; FOLLOW UP; HEMATOLOGICAL PARAMETERS; HOSPITALIZATION; HUMAN; INDIAN; LABORATORY TEST; LEUKOCYTE COUNT; LEUKOPENIA; LIVER TOXICITY; LOW DRUG DOSE; MALE; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; PAIN; PAINFUL CRISIS; PATIENT MONITORING; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; RASH; RETICULOCYTE COUNT; SCHOOL CHILD; SICKLE CELL ANEMIA; SIDE EFFECT; TOXICITY; TREATMENT OUTCOME; VASCULAR DISEASE; VASOOCCLUSIVE CRISIS;

ADOLESCENT; ANEMIA, SICKLE CELL; ANTISICKLING AGENTS; BLOOD TRANSFUSION; CHILD; FEMALE; FETAL HEMOGLOBIN; FOLLOW-UP STUDIES; HOSPITALIZATION; HUMANS; HYDROXYUREA; MALE; PAIN; TREATMENT OUTCOME;

EID: 84862907017     PISSN: 03630269     EISSN: 1532432X     Source Type: Journal    
DOI: 10.3109/03630269.2012.697948     Document Type: Article

References (24)

1. Weatherall DJ. The inherited disorders of haemoglobin: an increasingly neglected global health burden. Indian J Med Res. 2011;134(4):493-497.
2. Mohanty D, Mukherjee MB. Sickle cell disease in India. Curr Opin Hematol. 2002;9(2):117-122.
3. Mukherjee MB, Lu CY, Ducrocq R, et al. R. Effect of α-thalassemia on sickle-cell anemia linked to the Arab-Indian haplotype in India. Am J Hematol. 1997;55(2):104-109.
4. Singh H, Dulhani N, Kumar BN, Singh P, Tiwari P. Effective control of sickle cell disease with hydroxyurea therapy. Indian J Pharmacol. 2010;42(1):32-35.
5. Italia K, Jain D, Gattani S, et al. Hydroxyurea in sickle cell disease-a study of clinico-pharmacological efficacy in the Indian haplotype. Blood Cells Mol Dis. 2009;42(1):25-31.
6. Segal JB, Strouse JJ, Beach MC, et al. Hydroxyurea for the treatment of sickle cell disease. Evid Rep Technol Assess (Full Rep). 2008;(165):1-95.
7. Olivieri NF, Vichinsky EP. Hydroxyurea in children with sickle cell disease: impact on splenic function and compliance with therapy. J Pediatr Hematol Oncol. 1998;20(1):26-31.
8. Kinney TR, Helms RW, O'Branski EE, et al. Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group. Blood. 1999;94 (5):1550-1554.
9. Steinberg MH, McCarthy WF, Castro O, et al. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia and MSH Patients' Follow-Up. Am J Hematol. 2010;85(6):403-408.
10. Hankins JS, Ware RE, Rogers ZR, et al. Long term hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension study. Blood. 2005;106(7):2269-2275.
11. Santos A, Pinheiro V, Anjos C, et al. Scintigraphic follow-up of the effects of therapy with hydroxyurea on splenic function in patients with sickle cell disease. Eur J Nucl Med Mol Imaging. 2002;29(4):536-541.
12. Svarch E, Machín S, Nieves RM, Mancia de Reyes AG, Navarrete M, Rodríguez H. Hydroxyurea treatment in children with sickle cell anemia in Central America and the Caribbean countries. Pediatr Blood Cancer. 2006;47(1):111-112.
13. Strouse JJ, Lanzkron S, Beach MC, et al. Hydroxyurea for sickle cell disease: a systematic review for efficacy and toxicity in children. Pediatrics. 2008;122(6):1332-1342.
14. Elford HL. Effect of hydroxyurea on ribonucleotide reductase. Biochem Biophys Res Commun. 1968;33(1):129-135.
15. Snyder RD. The role of deoxynucleoside triphosphate pools in the inhibition of DNA-excision repair and replication in human cells by hydroxyurea. Mutat Res. 1984;131(3-4):163-172.
16. Zhou B, Mo X, Liu X, Qiu W, Yen Y. Human ribonucleotide reductase M2 subunit gene amplification and transcriptional regulation in a homogeneous staining chromosome region responsible for the mechanisms of drug resistance. Cytogenet Cell Genet. 2001;95(1-2):34-42.
17. Mabaera R, West RJ, Conine SJ, et al. A cell stress signaling model of fetal hemoglobin induction: what doesn't kill red blood cells may make them stronger. Exp Hematol. 2008;36(9):1057-1072.
18. Alcaín FJ, Löw H, Crane FL, Navas P. Iron chelators hydroxyurea and bathophenanthroline disulfonate inhibit DNA synthesis by different pathways. Biochem Mol Biol Int. 1994;34(2):273-279.
19. Cokic VP, Smith RD, Beleslin-Cokic BB, et al. Hydroxyurea induces fetal hemoglobin by the nitric oxide-dependent activation of soluble guanylyl cyclase. J Clin Invest. 2003;111(2):231-239.
20. Huang J, Yakubu M, Kim-Shapiro DB, King SB. Rat liver-mediated metabolism of hydroxyurea to nitric oxide. Free Radic Biol Med. 2006;40(9):1675-1681.
21. Zimmerman SA, Schultz WH, Davis JS, et al. Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease. Blood. 2004;103(6):2039-2045.
22. Ware RE, Eggleston B, Redding-Lallinger R, et al. Predictors of fetal hemoglobin response in children with sickle cell anemia receiving hydroxyurea therapy. Blood. 2002;99(1):10-14.
23. Ware RE, Despotovic JM, Mortier NA, et al. Pharmacokinetics, pharmacodynamics, and pharmacogenetics of hydroxyurea treatment for children with sickle cell anemia. Blood. 2011;118(18):4985-4991.
24. Ware RE. How I use hydroxyurea to treat young patients with sickle cell anemia. Blood. 2010;115 (26):5300-5311.